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ABSTRACT
RAS proteins (KRAS4A, KRAS4B, NRAS and HRAS) function
as GDP–GTP-regulated binary on-off switches, which regulate
cytoplasmic signaling networks that control diverse normal cellular
processes. Gain-of-function missense mutations in RAS genes are
found in ∼25% of human cancers, prompting interest in identifying
anti-RAS therapeutic strategies for cancer treatment. However,
despite more than three decades of intense effort, no anti-RAS
therapies have reached clinical application. Contributing to this
failure has been an underestimation of the complexities of RAS.
First, there is now appreciation that the four human RAS proteins are
not functionally identical. Second, with >130 different missense
mutations found in cancer, there is an emerging view that there are
mutation-specific consequences on RAS structure, biochemistry and
biology, and mutation-selective therapeutic strategies are needed. In
this Cell Science at a Glance article and accompanying poster, we
provide a snapshot of the differences between RAS isoforms and
mutations, as well as the current status of anti-RAS drug-discovery
efforts.
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Introduction
Mutations in the RAS gene were first reported in cancer
over 30 years ago, and numerous studies have since validated
mutant RAS as a driver of tumor initiation and maintenance (Cox
and Der, 2010). The three human RAS genes [i.e. Kirsten rat
sarcoma viral oncogene homolog (KRAS), neuroblastoma RAS viral
(v-ras) oncogene homolog (NRAS) and Harvey rat sarcoma viral
oncogene homolog (HRAS)] encode four RAS proteins, with two
KRAS isoforms that arise from alternative RNA splicing (KRAS4A
and KRAS4B). Although KRAS4B is the predominant splice
variant and expressed in many tissues – contributing to its focus in
cancer studies – there is significant KRAS4A expression in some
tissues (Tsai et al., 2015). RAS GTPases cycle between the GDP-
bound inactive and GTP-bound active states with the help of
guanine nucleotide exchange factors (RASGEFs) that promote
University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer
Center, Chapel Hill, NC 27514, USA.
*Author for correspondence (cjder@med.unc.edu)
1
© 2016. Published by The Company of Biologists Ltd | Journal of Cell Science (2016) 0, 1-6 doi:10.1242/jcs.182873
Jo
u
rn
al
o
f
Ce
ll
Sc
ie
n
ce
•
A
d
va
n
ce
ar
ti
cl
e
 JCS Advance Online Article. Posted on 16 March 2016
activation, and GTPase-activating proteins (RASGAPs) that
inactivate RAS by catalyzing GTP hydrolysis. Once activated,
RAS-GTP binds to and activates a spectrum of downstream
effectors with distinct catalytic functions (see Box 1).
Missense gain-of-function mutations in all three RAS genes are
found in 27% of all human cancers, with 98% of the mutations at
one of three mutational hotspots: G12, G13 and Q61 (COSMIC
v75). Conventionally, mutant RAS is considered to be defective in
GAP-mediated GTP hydrolysis, which results in an accumulation
of constitutively GTP-bound RAS in cells. Additionally, the
involvement of RAS in cancer is greater than that indicated by its
mutation frequency; perturbations in GDP–GTP regulation, loss of
GAPs [e.g. neurofibromin 1 (NF1)] or persistent receptor tyrosine
kinase-mediated activation of GEFs [e.g. son of sevenless 1
(SOS1)] are additional mechanisms of RAS activation in cancer.
Finally, recent studies support a role for the remaining wild-type
(WT) RAS proteins present in RAS-mutant cancers in
contributing to cancer growth (Grabocka et al., 2014; Lim et al.,
2008; Young et al., 2013), although other studies suggest that WT
RAS can act as a tumor suppressor (Bremner and Balmain, 1990;
Qiu et al., 2011; To et al., 2013; Weyandt et al., 2015; Zhang
et al., 2001).
Historically, the majority of biochemical and structural studies
of RAS have focused on HRAS (Vetter, 2014). However, HRAS is
the least frequently mutated RAS isoform in human cancers (4%),
whereas KRAS is the predominantly mutated isoform (85%),
followed by NRAS (11%). Furthermore, the G12V mutation has
been traditionally characterized as the ‘poster child’ for oncogenic
RAS when defining the biological properties of mutant RAS in
cancer. However, there is increasing evidence that mutations at
each of the three missense-mutation hotspots (G12, G13 and Q61)
have distinct structural and biochemical defects (Buhrman et al.,
2007; Burd et al., 2014; Hunter et al., 2015; Smith et al., 2013).
Evidence that different amino acid substitutions at any one hotspot
can have differential oncogenic potencies as well as distinct
functional consequences (Ihle et al., 2012) adds an additional layer
of complexity, suggesting that ‘not all RAS mutants are created
equal’. Further, there are striking cancer-type-specific and isoform-
distinct differences in the observed frequencies of specific RAS
missense mutations at the three hotspots (Cox et al., 2014;
Prior et al., 2012). With increasing experimental evidence
supporting RAS isoform and mutation differences, as well as
cell-specific and genetic-context-specific differences, there is
growing speculation that there will not be one simple anti-RAS
therapeutic approach for all RAS mutant cancers. Instead, cancer-
type-specific therapeutic strategies must be determined for
different subsets of RAS mutations. Here, we summarize our
current understanding of RAS-isoform- and RAS-mutation-
specific functional differences.
RAS isoform differences and post-translational
modifications
The three RAS genes encode four RAS protein isoforms that are
highly similar in primary sequence (82-90% amino acid (aa)
sequence identity), structure and biochemical properties (GTP
binding, hydrolysis and prenylation) (see poster). The N-terminal
164 residues comprise the G domain, which is involved in GTP
binding and hydrolysis. Within the G domain are switch I (SI) and
switch II (SII), regions that change in conformation during GDP–
GTP cycling and are the main determinants in effector binding. In
contrast, the C-terminal hypervariable region (HVR) shares little
sequence similarity.
Although the sequence divergence of RAS proteins is typically
thought of as residing solely within the HVR, there is a second
region of sequence divergence. RAS isoforms share 100% sequence
identity in the N-terminus of the G domain termed the effector lobe
(aa 1–86), but there is only 82% sequence similarity within residues
87–166, termed the allosteric lobe (Buhrman et al., 2011). Whether
these sequence differences contribute to the functional differences
of RAS isoforms is still largely understudied. However, the
allosteric lobe has been suggested to play a role in SII
conformation and membrane orientation (Parker and Mattos,
2015), and RAS membrane orientation has been shown to
regulate effector utilization (Abankwa et al., 2008, 2010).
There are striking cancer-type-specific mutational profiles of
RAS gene isoforms in cancer, suggesting tissue-distinct roles for
RAS in driving oncogenesis. For example, there is near-exclusive
mutation of KRAS in pancreatic ductal, lung and colorectal
carcinoma, whereas NRAS is the predominant isoform mutated in
cutaneous melanoma (Cox et al., 2014). In contrast, HRAS
mutations predominate in head and neck squamous cell
carcinoma. Recent mouse model studies have begun to address
the issue of why specific RAS gene isoforms are preferentially
mutated in specific cancers. In one study, the Kras G12D mutation
but not the Nras G12D mutation promoted colon cancer
development in Apc-deficient mice, supporting the ability of
KRAS but not NRAS to initiate the formation of colon cancer
(Haigis et al., 2008). In contrast, another mouse carcinogenesis
model showed that the preferential basis for Kras mutation in lung
cancer was not due to distinct functional differences between RAS
isoforms but, rather, the distinct regulation of expression of the
RAS gene isoform (Westcott et al., 2015). Thus, whether a specific
RAS gene is required for cancer development arising from different
tissues remains unresolved.
RAS isoform differences have been identified at the level of
protein translation and provide one possible explanation for why
KRAS is the predominantly mutated isoform in cancer. Unlike
HRAS, the KRAS DNA coding sequence has a high frequency of
rare codons, resulting in poor KRAS protein translation and
expression (Lampson et al., 2013). As RAS mutations are the
initiating genetic events in many cancers, it has been proposed that
the high expression of activated HRAS, but not KRAS, induces
senescence. Consequently, a cell with mutated KRAS will persist to
allow subsequent genetic events in order to promote tumor
progression. Supporting this possibility, it was found that mice
harboring a codon-optimized KRAS coding sequence – resulting in
Box 1. RAS effector signaling
Activated GTP-bound RAS binds preferentially to its downstream
effectors. RAS-GTP preferentially binds to RAS-binding-domain (RBD)
or RAS-association (RA)-domain-containing effectors (see poster).
Although the RBD and RA domains do not share primary sequence
similarity, they are structurally related and share the topology of the
ubiquitin superfold (Kiel et al., 2005; Wohlgemuth et al., 2005). There are
at least 11 distinct RAS effector families, each of which activates a
distinct protein signaling cascade (Vigil et al., 2010). There are
substantial cell culture and mouse model analyses that support the
driving role of four families (i.e. RAF, PI3K, RalGEF and TIAM1) in RAS-
driven oncogenesis (Bryant et al., 2014). Support for effector–driver
function is also indicated by the inclusion of components of each effector
signaling pathway in the Cancer Gene Census, i.e. those genes for
which mutations have been causally implicated in cancers (COSMIC
v75). In particular, mutations of BRAF (19%) and PI3KCA (10%) are
commonly found in many cancers.
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increased KRAS protein expression – show significantly reduced
tumor formation (Pershing et al., 2015).
Currently, differences in RAS isoforms have been ascribed
largely to sequence differences within their C-terminal HVRs, a site
at which RAS proteins are differentially lipid-modified. KRAS4A
and KRAS4B have polybasic sequences that facilitate membrane-
association in acidic membrane regions (Gelabert-Baldrich et al.,
2014). In addition, KRAS4A and NRAS are covalently modified by
a single palmitic acid, whereas HRAS can be palmitoylated at
two sites within the HVR. Palmitoylation is reversible and
substoichiometric. The lipidation profile of each isoform has been
shown to dictate membrane localization (Cox et al., 2015; Jang
et al., 2015). Recent evidence indicates that the palmitoylation state
of HRAS and NRAS also dictates their distribution within the Golgi
membrane, with HRAS distributed throughout and NRAS localized
to the cis-Golgi (Lynch et al., 2015). At the plasma membrane,
HRAS is in the GTP-bound statewhen in non-ordered lipid domains
and is GDP-bound when in lipid rafts (Rotblat et al., 2004); yet, the
opposite seems to be true for NRAS (Eisenberg et al., 2011).
KRAS4B is distinguished from other RAS isoforms in having a
phosphorylation site (S181) within the HVR that acts as an
electrostatic farnesyl switch, causing KRAS4B translocation from
the plasma membrane to endomembrane compartments (Barcelo
et al., 2014; Quatela et al., 2008) (see poster). This altered
subcellular localization differentially influences effector
engagement and biological activity of KRAS4B. NRAS has been
shown to be phosphorylated by the Src tyrosine kinase at Y32
(Bunda et al., 2014). This modification was shown to decrease
NRAS affinity to the RAS-binding domain (RBD) of RAF (see
Box 1) and increase the affinity to RasGAP, thereby providing a
new level of regulation not previously observed for RAS family
GTPases. Additionally, HRAS can be phosphorylated at Y137 by
the ABL tyrosine kinase, resulting in increased RAF interaction and
decreased intrinsic GTP hydrolysis (Ting et al., 2015).
C-terminal to the HVR, all RAS proteins terminate with a CAAX
tetrapeptide motif (C, cysteine; A, aliphatic aa; X, any aa) that
signals for three sequential C-terminal post-translational
modifications that enhance hydrophobicity and promote plasma
membrane association (Ahearn et al., 2012). Whereas all RAS
CAAX motifs can be modified by the farnesyltransferase-catalyzed
addition of a C15 farnesyl isoprenoid lipid, in the absence of
farnesyltransferase activity, KRAS4B and NRAS can be modified
by geranylgeranyltransferase-I-catalyzed addition of a C20
geranylgeranyl isoprenoid; this accounts for the failure of
farnesyltransferase inhibitors to effectively block the membrane
association of the RAS isoforms most commonly mutated in cancer.
Additionally, RAS isoforms have been observed to be
differentially ubiquitylated. HRAS has been shown to be mono-
and di-ubiquitylated, and ubiquitylation internalizes HRAS from the
plasma membrane, limiting HRAS-mediated RAF signaling (Jura
et al., 2006). NRAS was also shown to be similarly ubiquitylated,
whereas KRAS has later shown to be mono/di- ubiquitylated (Sasaki
et al., 2011). Monoubiquitylation of KRAS4B at K147 increased
effector binding, whereas ubiquitylation-deficient KRAS G12V
showed reduced oncogenic function (Sasaki et al., 2011). However,
no consequences regarding subcellular localization were observed.
Ubiquitylation at K147 enhanced WT KRAS-GTP formation and a
later study identified impaired GAP interaction to account for this
altered property (Baker et al., 2013a). HRAS has been shown to be
ubiquitylated at K117, and this modification accelerated nucleotide
exchange and activation (Baker et al., 2013b). Given the differentially
observed ubiquitylation patterns that have been reported between
RAS isoforms, RAS ubiquitylation is likely to have distinct roles in
different cell types based on the isoform and site of modification.
KRAS4B has also been shown to be acetylated at K104.
Acetylation has been proposed to disrupt the conformation of SII,
impairing GEF-mediated activation and, consequently, reducing
effector activation and transforming potency (Yang et al., 2012).
Whether other RAS isoforms become acetylated remains to be
determined.
Cancer-specific hotspot frequency variations
The RAS gene isoforms are also distinguished by their striking
differences in the mutation frequency at each of the three hotspots
(G12, G13 andQ61) (see poster). G12mutations comprise 83% of all
KRAS mutations, followed by G13 mutations (14%), whereas Q61
mutations are rare (2%). In striking contrast, Q61 is the predominantly
mutated hotspot inNRAS, followed byG12 andG13.HRASdisplays
an intermediate pattern, with comparable mutation frequencies of
G12, G13 and Q61. Furthermore, the mutation frequency within one
RAS isoform can exhibit significant differences between cancer
types. NRAS Q61 mutations comprise the most frequently mutated
hotspot in melanoma, whereas G12 mutations are rare. In contrast,
NRAS G12 mutations are favored in acute myeloid leukemia. KRAS
mutations in pancreatic ductal adenocarcinoma (PDAC) are
dominated by G12 mutations, whereas G13 and Q61 mutations are
rare.However, there is a relatively high frequencyofG13mutations in
colorectal adenocarcinoma (CRC). These patterns suggest the
intriguing possibility that different RAS mutations have different
functional consequences and the properties crucial for their oncogenic
functions vary depending on the tissue of origin.
There are probably qualitative and quantitative reasons for
hotspot mutation preferences. Mice harboring a codon-optimized
KRAS coding sequence showed a shift of chemical carcinogen
urethane-induced lung tumor formation, with G12V/D-activating
mutations now favored over Q61/R mutations seen in the authentic
Kras gene in mice (Pershing et al., 2015). The Kras Q61 mutant
tumors showed greater ERK activation, arguing for greater potency
within this hotspot. Another study found that, in p16INK4a-
deficient mice, the frequency of metastatic melanoma initiation for
Box 2. Approaches for targeting RAS
The past and current efforts to develop antagonists of mutant RAS
function include direct and indirect approaches. Once considered to be
infeasible, recent studies have identified small molecules that directly
bind to RAS and disrupt crucial functions of RAS, including (i) GDP–GTP
regulation and interaction with its effectors. The development of G12C-
selective inhibitors that target the thiol in order to inhibit GTP binding –
locking RAS in an inactive state so it cannot interact with its effectors –
have been recently described (Hunter et al., 2014; Ostrem et al., 2013).
Other molecules that block RAS interaction with the SOS1 RASGEF
(Maurer et al., 2012; Sun et al., 2012) or effectors (Shima et al., 2013)
have also been identified. Indirect approaches include (ii) inhibition of
enzymes that target the RAS CAAX motif in order to prevent membrane
association of RAS (e.g. farnesyltransferase) (Cox et al., 2015) or of
proteins that facilitate RAS trafficking to the plasma membrane
(phosphodiesterase delta) (Zimmermann et al., 2013), (iii) inhibitors of
downstream effector signaling (e.g. RAF or PI3K effectors) (Fruman and
Rommel, 2014; Samatar and Poulikakos, 2014), (iv) inhibitors of
processes that support the increased metabolic needs of cancer cells
(e.g. macropinocytosis, autophagy, glucose and glutamine metabolism),
(v) unbiased genetic or chemical screens for synthetic lethal interactors
(Barbie et al., 2009; Kumar et al., 2012; Luo et al., 2009; Sarthy et al.,
2007; Scholl et al., 2009) and (vi) RNA interference (RNAi) of KRAS
expression (Pecot et al., 2014; Xue et al., 2014; Yuan et al., 2014).
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Nras Q61R was increased more than 20-fold compared with Nras
G12D (Burd et al., 2014). A clear mechanistic basis for the
enhanced oncogenic activities of NRAS Q61 mutants in melanoma
remains to be established.
RASmutation hotspots – structural, biological and functional
differences
Whereas much of the current ‘dogma’ on the consequences of
missense mutations on RAS function was established from the study
of the HRAS G12V mutation, there is growing evidence and
appreciation for the different functional outcomes ofRASmutations at
aa positions 12, 13 and 61. In biochemical studies, it has been shown
that the G12Vmutation leads to a loss ofGAP sensitivity, whereas the
Q61L mutation leads to reduced intrinsic hydrolysis and GAP
sensitivity, as well as increased intrinsic nucleotide exchange (Smith
et al., 2013). The RASG13Dmutant shows decreasedGAP-mediated
hydrolysis and a massively increased rate of intrinsic nucleotide
exchange compared to that of WT RAS (Smith et al., 2013).
Structural analysis of several RAS G12 mutant crystal structures
revealed that only the G12R mutation alters the structure of RAS
relative to the WT structure (see poster). The structural perturbation
within SII appears to be a result of the arginine side chain displacing
the glutamine residue at position 61 in the nucleotide binding site, a
residue that is crucial for GTP hydrolysis. Interestingly, several RAS
Q61 mutant structures show alterations in SII (see poster).
Molecular dynamics simulations have indicated a biophysical
rationale for the biochemical differences between G12 and G13
mutations. Using a crystal structure model of HRAS bound to
p120RASGAP to model hydrolysis, the G12V mutation resulted in
the displacement of the catalytic water and of Q61, leading to a loss
of GAP sensitivity. However, an increase in the dynamics of the γ
phosphate, SII, catalytic water and arginine finger of p120RASGAP
was observed in G13V-mutant RAS. Thus, the increased dynamics
of these regions accounted for the decreased GAP sensitivity of this
mutant (Khrenova et al., 2014).
HRASWT and HRASQ61L also showed altered dynamics when
bound to RAF-RBD (Fetics et al., 2015). The RAS Q61L mutation
resulted in allosteric changes in the structure of RAS in regions
distal from the site of mutation. Using crystal structures of HRAS
WT and HRAS Q61L bound to RAF-RBD in conjunction with
computational modeling, the Q61L mutation was shown to cause
increased flexibility in SII; however, when HRAS Q61L was bound
to RAF, SII was significantly more rigid relative to HRASWT. This
is in contrast to the observation made by using HRASWT, in that its
binding to RAF increases the flexibility of SII. Further, the Q61L
mutation increased the flexibility of the allosteric lobe (residues R97
and Y137), which increased the rigidity of loop 4 in the RAF-RBD,
a region that is of key importance for interaction between RAF and
MEK (Fetics et al., 2015). These results support the possibility that
the RAS hotspot mutations have unique consequences on RAS
structure and function.
There is intriguing evidence that mutations at different hotspots
can impact the clinical outcome and treatment of cancer patients.
Initial studies using anti-epidermal growth factor receptor (EGFR)
therapy to treat CRC prompted the US Food and Drug
Administration (FDA) to revise their recommendation to exclude
patients with KRAS G12 or G13 mutations from treatment (Allegra
et al., 2009). EGFR is a receptor tyrosine kinase that is positioned
upstream of RAS. However, subsequent analyses has suggested that
CRC patients with KRAS G13 mutations benefit from anti-EGFR
therapy (Tejpar et al., 2012). This issue continues to evolve (Van
Cutsem et al., 2015) because the National Comprehensive Cancer
Network recommendation now indicates that CRC patients with any
KRAS orNRASmutation, including those of Q61 and A146, will not
benefit from anti-EGFR therapy (Tran et al., 2015).
A limited number of studies have observed different clinical
outcomes for different KRAS mutations in PDAC. One study found
that KRAS G12D and G12R mutations are negative prognostic
factors for overall survival (Ogura et al., 2013). However, a second
study found that the presence of KRAS G12R alone correlates with
increased overall survival, whereas the KRAS G12D mutation
resulted in the shortest overall survival (Faris et al., 2014). Recent
analyses observed that patients with KRAS Q61 mutations showed
significantly improved survival (Witkiewicz et al., 2015) and,
interestingly, Q61-mutant tumors showed decreased ERK activation
in these samples. In summary, these observations indicate that more
consideration with regard to the site of mutation in the context of the
cancer type of the patient is necessary when determining the
prognostic value of the mutation.
Mutation-dependent signaling
Although six possible single-base-change missense mutations can
occur at the codons for G12, G13 and Q61, their frequencies are not
uniform (see poster). At the codon for G12, G12D is the predominant
KRAS (41%) and NRAS (52%) mutation, whereas G12V
predominates in HRAS (57%). At the codon for G13, G13D is the
most frequent substitution forKRAS (89%) andNRAS (50%); yet it is
rare inHRAS (3%), where G13R (85%) is the predominant mutation.
Additionally, at the codon for Q61, Q61H is the predominant KRAS
mutation (58%), yet it is rare in both NRAS (6%) and HRAS (5%), in
which Q61R is the main substitution (47% and 43%, respectably).
Finally, there are cancer-type differences regarding the substitutions
seen at a given RAS residue. Considering, for example, the KRAS
codon for G12, the predominant substitution is G12D in PDAC,
followed by G12V. In contrast, in lung adenocarcinoma (LAC), the
main substitution is G12C, which is rare in PDAC (3%) (Cox et al.,
2014). Although tissue-specific exposure to certain carcinogens is
likely to contribute to these distinct frequencies, it is possible that
different substitutions at any one position do not have equivalent
biological outcomes. These isoform differences also suggest the
intriguing possibility that the samemutation does not have equivalent
consequences in the different RAS isoforms.
The concept that different aa substitutions have distinct functional
consequences at a specific mutation hotspot was first revealed in
mutagenesis studies. When the consequences of all 19 possible aa
mutations at the codon for G12 were studied in HRAS, a wide range
of oncogenic potential was observed (Seeburg et al., 1984). A
similar study assessed the consequences of 17 different mutations
on HRAS Q61 (Der et al., 1986). Although all 17 mutants shared
comparable defects in GTP hydrolysis activity in vitro, the Q61P
and Q61E mutations did not show increased transforming ability
relative to HRAS WT in mouse fibroblast focus-formation assays.
Emerging evidence suggests that there are mutation-selective
consequences on effector signaling. A comparison of KRAS G12C,
G12V and G12D mutations in non-small cell lung cancer cell lines
revealed mutation-specific alterations regarding effector preference
(Ihle et al., 2012). For instance, increased AKT phosphorylation was
observed in G12D but not G12C KRAS-expressing cell lines,
whereas increased levels of RAL-GTP were detected in G12CKRAS
cell lines (Ihle et al., 2012). In another study comparing the effector
preference of KRAS G12 and KRAS G13 mutants by using
quantitative proteomics to search for non-traditional KRAS-
mediated pathways, the colon cancer stem cell marker DCLK1 and
the receptor tyrosine kinase MET were both found to be upregulated
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in G12-mutant-expressing KRAS cells, whereas the tight-junction
protein ZO-2was upregulated inKRAS-G13D-expressing cells when
compared to parental lines (Hammond et al., 2015). These studies
indicate that individual RAS mutants can signal differently,
suggesting that each RAS mutant requires unique pharmacological
targeting.
Conclusions
After more than three decades of intense research focus, our
understanding of RAS structure, biochemistry and biology is,
indeed, very comprehensive. Yet, much remains to be elucidated
and many issues are still poorly understood. Without any anti-RAS
therapies in the clinic, there is now better recognition of these
remaining challenges, prompting a ‘renaissance’ in RAS research
and the initiation of the US National Cancer Institute RAS Initiative
(Ledford, 2015; Thompson, 2013). Among these issues is the need
to delineate the distinct roles that each RAS isoform serves in
normal and disease settings. Additionally, until recently, the field
has simplistically cataloged cancers as either WT or mutant for
RAS; yet, more than one-hundred different missense mutations have
been found in cancer. With the arrival of ‘personalized medicine’, a
greater attention to and appreciation for RAS-isoform- and RAS-
mutation-specific differences will be important in the development
of mutation-selective anti-RAS strategies.
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